International – Moderna launches COVID-19 vaccine booster study to address new variants

The phase 2 trial amendment has enrolled 60 participants who have already received Moderna’s original mRNA-1273 vaccine. They will receive a single booster dose of a modified candidate addressing the B.1.351 variant or a multivalent booster candidate.

The variant-specific booster candidate – mRNA-1273.351 – encodes for the spike protein of the SARS-CoV-2 variant B.1.351, first discovered in South Africa.

Moderna will evaluate two doses of mRNA-1273.351 – 20 µg and 50 µg – to determine if this candidate can act as a booster to address and improve protection against the B.1.351 variant…